C4 Therapeutics

c4therapeutics.com

C4 Therapeutics is a clinical-stage biotechnology company developing a new generation of medicines that harness targeted protein degradation (TPD) to transform how disease is treated. Their innovative Degronimid™ platform allows for the selective targeting and degradation of disease-causing proteins, which can potentially address a wide range of diseases previously considered undruggable. With a leadership team experienced in biopharma, C4T aims to make significant advancements in therapeutic options through collaborations and proprietary programs, positioning itself strongly in the biotechnology market.